Clinical Trial Update: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab [Phase 2]

View source ↗

Summary

A Phase 2 trial of the complement inhibitor eculizumab for anti-neutrophil cytoplasmic antibody-associated vasculitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Status: WITHDRAWN